Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ElectroCore brings in neurogastroenterologist to lead clinical activities

This article was originally published in Clinica

Executive Summary

Electrocore, a company specializing in noninvasive vagal nerve stimulation (VNS), has appointed Dr Nader Youssef as Chief Medical Officer. Nader was previously Executive Director of GI Global Clinical Development and Medical Affairs for NPS Pharmaceuticals, where he was responsible for regulatory and development strategy and helped NPS secure US and EU marketing approvals for gastrointestinal drugs. Prior to NPS, he was at AstraZeneca, where his focus was also on GI pain and motility. His expertise in this area will be beneficial to electroCore as it expands its gammaCore noninvasive VNS platform to new indications within gastroenterology and other fields. gammCore was CE-marked in 2011 for treatment of migraine and cluster headaches.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel